It's a nice theory, but Solagran doesn't release (positive) sensitive information for the simple reason that it doesn't have any. The trial results don't show anything better than placebo, and if you listened to Vagif at the EGM, you would understand how much can be said and said and said, and yet you end up going around and around and around in circles.
Sooner or later, the market will correct Solagran's inflated market cap to sensible levels. A manufacturing licence is a long way off, with the key facility requiring a complete overhaul, and other major issues with impurities that the RMOH has flagged as needing their urgent attention.
There is a disturbing gap between actual revenue and expecations, and the market will react to close that soon. In the meantime, enjoy the warm glow of a completely uneventful EGM. All talk, no action.
SLA Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held
